Christopher E. Kinum, principal, and F. John Fatigati, senior vice president of the Chatham, NJ-based Garibaldi Group, represented Sankyo with the original transaction, the renewal and the expansion. Michael Nevins was the in-house representative for the property's owner, Mack-Cali Realty of Cranford, NJ. "This transaction is another indicator of New Jersey's role in the pharmaceutical industry," according to Fsatigati.
Sankyo develops new classes of medicines for a variety of diseases, including cancer, cardiovascular disease and metabolic disorders. Perhaps its best known brand is the cholesterol-lowering drug, WelChol.
© Touchpoint Markets, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to asset-and-logo-licensing@alm.com. For more inforrmation visit Asset & Logo Licensing.
